| Wave Life Sciences is a clinical-stage genetic medicines company. Co. has a pipeline of programs. Co.'s primary programs are designed to treat genetic diseases, which include: WVE-N531 (splicing), its exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006 (editing), its SERPINA1 molecule for the treatment of alpha-1 antitrypsin deficiency; WVE-003 (silencing), its mutant huntingtin single nucleotide polymorphism three molecule for the treatment of Huntington's disease; and WVE-004 (silencing), its C9orf72 molecule for the treatment of C9orf72-associated amyotrophic lateral sclerosis and frontotemporal dementia. We show 38 historical shares outstanding datapoints in our WVE shares outstanding history coverage, used to compute WVE market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing WVE market cap history over the course of time is important for investors
interested in comparing WVE's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of WVE versus a peer is one thing; comparing
WVE market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like WVE can fluctuate over the course of history.
With this page we aim to empower investors researching WVE by allowing them to research the WVE market cap history.